Isaac Levy, MD
Hematology-Oncology · Pembroke Pines, FLNPI 1871577221
Payments from drug & device makers
Across 1,471 payments — averaging $2265.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.9M
- Eli Lilly$199K
- Karyopharm Therapeutics Inc.$36K
- Sanofi$35K
- Incyte Corporation$30K
- Amgen$24K
- plus $66K from 54 others
Across 7 payments — averaging $2471.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$14K
- Eli Lilly$3K
- Spectrum Pharmaceuticals Inc.$385
What the payments were for
- Consulting fees$23,27743%
- Speaking & faculty fees$1,0002%
- Travel & lodging$1,6513%
- Food & beverage$27,04249%
- Education$1,4963%
- Other$2991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 64 | $769,203 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 40 | $711,396 |
| ImbruvicaIbrutinib | 37 | $574,380 |
| BrukinsaZanubrutinib | 36 | $547,817 |
| ErleadaApalutamide | 18 | $281,555 |
| TasignaNilotinib Hcl | 12 | $226,062 |
| TagrissoOsimertinib Mesylate | 12 | $209,515 |
| Abiraterone Acetate | 21 | $118,418 |
| DarzalexDaratumumab | 24 | $114,998 |
| PromactaEltrombopag Olamine | 12 | $86,423 |
| PerjetaPertuzumab | 12 | $76,755 |
| OrgovyxRelugolix | 19 | $59,651 |
| XgevaDenosumab | 17 | $54,974 |
| Imatinib Mesylate | 28 | $20,983 |
| EliquisApixaban | 25 | $20,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $83 | $574,38037 claims |
| Beigene USA, Inc.Brukinsa | $697 | $547,81736 claims |
| Johnson & JohnsonErleada, Darzalex | $2,452 | $396,55242 claims |
| NovartisTasigna, Promacta | $2,943,405 | $312,48524 claims |
| AstraZenecaTagrisso | $14,904 | $209,51512 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $103 | $118,41821 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $102 | $59,65119 claims |
| AmgenXgeva | $23,891 | $54,97417 claims |
| PfizerEliquis | $11,955 | $20,20825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Pembroke Pines
- Amer RassamTallahassee$11K
- Roger FebresKissimmee$11K
- Meri MuminovicMiramar$6K
- Steven WeissCoral Springs$6K
- Carlos BarburHialeah$5K
- Bruce StechmillerSt Augustine$0
- Seongseok YunTampa$0
- Peter MoussaTampa$0
- Andrew DeniccoMiami$0
- Robert KilleenHoliday$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.